Format

Send to

Choose Destination
Clin Epidemiol. 2019 Mar 22;11:231-244. doi: 10.2147/CLEP.S170873. eCollection 2019.

Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden.

Author information

1
Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden, Krister.Lindmark@umu.se.
2
Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
3
Real-World & Analytics Solutions, IQVIA, Solna, Sweden.
4
Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland.
5
Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden.
6
Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
7
Department for Medical Sciences, Uppsala University, Uppsala, Sweden.

Abstract

Purpose:

The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.

Methods:

Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005-2013) and electronic medical records (cohort 2, 2010-2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.

Results:

Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06-1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02-1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997-2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time).

Conclusion:

The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF.

KEYWORDS:

diagnosis; heart failure; incidence rate; mortality; prevalence; real-world

Conflict of interest statement

Disclosure K Lindmark, K Boman, and M Olofsson received lecture grants and consultant fees from Novartis. J Stålhammar received reimbursement from Novartis via IQVIA for performing the study. R Schlienger is an employee of Novartis Pharma AG, Switzerland, and S Bruce Wirta is an employee of Novartis Sweden AB, Sweden. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center